Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07740564) titled 'Phase III Study of OT202 in Treating Moderate to Severe Dry Eye' on July 23.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Ocumension Therapeutics (Suzhou) Co., Ltd
Condition:
Dry Eye
Intervention:
Drug: OT202 conc 1%
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: August 2026
Target Sample Size: 842
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT0774...